GGrantIndex
← Leaderboards

Paul Christopher Boutros

Eastern Virginia Medical School

Google Scholar ↗PubMed ↗ORCID ↗
$16,156,127
Attributed
$23,269,968
Total exposure
14
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $10M · FY2016–25
$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$38,715,955 · 17

By mechanism

U54$14,490,262 · 2
R01$7,506,690 · 3
P30$5,807,500 · 7
U2C$4,343,434 · 3
U24$4,050,315 · 1
U01$2,517,754 · 1

Top collaborators

Others in their field

Top investigators on “Diagnosis”

Research focus

DiagnosisMalignant NeoplasmsMolecularData SetTumorCessation Of LifeResearch PersonnelBiopsyOperative Surgical ProceduresGenomicsBiological MarkersProgramsMalignant Neoplasm Of ProstateFosteringNeoplasm MetastasisBenchmarkingSamplingCohortPerformanceInnovationNewly DiagnosedStructureTechnologyArchitecture

Grant awards (52)

Cancer Center Support Grant (CCSG)$4,081,820
P30 · FY2025 · CA · contact PI
Tool Core- Boutros$2,439,661
U54 · FY2025 · HG · contact PI
Virginia-UCLA-Toronto Biomarker Characterization Center$843,355
U2C · FY2025 · CA
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer$839,781
R01 · FY2025 · CA
Cancer Research Career Enhancement and Related Activities (CRCERA)$255,115
P30 · FY2025 · CA · contact PI
Admin Core$255,115
P30 · FY2025 · CA · contact PI
Cancer Metabolism$255,113
P30 · FY2025 · CA · contact PI
Cancer Metabolism & Microenvironment$255,113
P30 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$255,113
P30 · FY2025 · CA · contact PI
Developmental Funds$255,113
P30 · FY2025 · CA · contact PI
Administrative Supplement to Cancer Center Support Grant (CCSG)$194,998
P30 · FY2025 · CA · contact PI
Core-Biomarker Development Laboratory$99,893
U2C · FY2025 · CA · contact PI
Building BRIDGEs: Coordinating Standards, Diversity, and Ethics to Advance Biomedical AI$2,465,005
U54 · FY2024 · HG
Tool Core- Boutros$1,324,809
U54 · FY2024 · HG · contact PI
Virginia-UCLA-Toronto Biomarker Characterization Center$801,603
U2C · FY2024 · CA
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer research$776,200
U24 · FY2024 · CA
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:$658,881
R01 · FY2024 · CA
Germline Determinants of Prostate Cancer Evolution$597,235
R01 · FY2024 · CA · contact PI
The Evolution of Sarcoma Drug Sensitivity through Time and Space$472,053
R01 · FY2024 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$318,066
R01 · FY2024 · CA
Core-Biomarker Development Laboratory$137,809
U2C · FY2024 · CA · contact PI
Building BRIDGEs: Coordinating Standards, Diversity, and Ethics to Advance Biomedical AI$2,477,517
U54 · FY2023 · HG
Tool Core- Boutros$1,333,866
U54 · FY2023 · HG · contact PI
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer research$800,850
U24 · FY2023 · CA
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:$679,692
R01 · FY2023 · CA
Germline Determinants of Prostate Cancer Evolution$628,946
R01 · FY2023 · CA · contact PI
Building BRIDGEs: Coordinating Standards, Diversity, and Ethics to Advance Biomedical AI$586,030
U54 · FY2023 · HG
Virginia-UCLA-Toronto Biomarker Characterization Center$569,990
U2C · FY2023 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$486,959
R01 · FY2023 · CA
Core-Biomarker Development Laboratory$384,479
U2C · FY2023 · CA · contact PI
The Evolution of Sarcoma Drug Sensitivity through Time and Space$334,806
R01 · FY2023 · CA
Virginia-UCLA-Toronto Biomarker Characterization Center$257,353
U2C · FY2023 · CA
Core-Biomarker Development Laboratory$111,454
U2C · FY2023 · CA · contact PI
Building BRIDGEs: Coordinating Standards, Diversity, and Ethics to Advance Biomedical AI$2,504,189
U54 · FY2022 · HG
Tool Core- Boutros$1,359,185
U54 · FY2022 · HG · contact PI
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer research$801,343
U24 · FY2022 · CA
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:$715,452
R01 · FY2022 · CA
Virginia-UCLA-Toronto Biomarker Characterization Center$664,127
U2C · FY2022 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$486,959
R01 · FY2022 · CA
Core-Biomarker Development Laboratory$473,371
U2C · FY2022 · CA · contact PI
Signaling Drivers of Sarcoma Drug Resistance$334,806
R01 · FY2022 · CA
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer research$818,213
U24 · FY2021 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$496,897
R01 · FY2021 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$220,035
U01 · FY2021 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$127,627
U01 · FY2021 · CA
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer research$853,709
U24 · FY2020 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$456,157
R01 · FY2020 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$433,053
U01 · FY2020 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$420,061
U01 · FY2019 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$432,349
U01 · FY2018 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$430,450
U01 · FY2017 · CA
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer$454,179
U01 · FY2016 · CA